Company Overview

Tandem Diabetes Care, Inc. is a publicly traded medical device company focused on the design, development, and commercialization of insulin delivery systems for people with diabetes. The company operates within the diabetes technology and medical devices industries, with a primary emphasis on insulin pump therapy and integrated diabetes management solutions. Tandem’s core revenue drivers include sales of its insulin pump hardware, related disposable supplies, and software-enabled diabetes management technologies. Its flagship products include the t:slim X2 insulin pump, the Mobi insulin delivery system, and associated infusion sets and cartridges. The company also generates recurring revenue through consumables and ongoing patient support services.

Tandem primarily serves individuals with type 1 diabetes and insulin-dependent type 2 diabetes, along with healthcare providers and diabetes clinics. A key aspect of its market positioning is its integration with continuous glucose monitoring (CGM) systems and automated insulin delivery algorithms, particularly through partnerships with CGM manufacturers. The company was founded in 2006 and is headquartered in San Diego, California. Tandem evolved from an early-stage insulin pump developer into a major participant in the automated insulin delivery market following FDA clearances for advanced hybrid closed-loop technologies and software update capabilities that allow remote feature upgrades without replacing hardware.

Business Operations

Tandem conducts its operations primarily through the development and commercialization of insulin delivery systems and related diabetes management technologies. The company reports revenue mainly from insulin pump sales and recurring sales of disposable supplies used with its pumps. Its principal business platforms include the t:slim family of pumps and the compact Tandem Mobi system. Tandem’s products incorporate proprietary software and insulin dosing algorithms, including Control-IQ technology, which automates insulin adjustments based on CGM data. The company also controls cloud-based data management tools and digital health integration capabilities that support patient monitoring and therapy optimization.

The company operates across both domestic and international markets, with direct sales operations in the United States and select international regions, alongside distributor relationships in additional countries. Tandem maintains strategic partnerships with glucose monitoring companies, most notably integrations with Dexcom CGM systems and collaborations involving Abbott glucose sensing technologies. The company has also expanded its technology portfolio through acquisitions, including Capillary Biomedical, which enhanced its infusion set development capabilities. Manufacturing activities are concentrated in the United States, while international commercialization continues to expand through regional distribution and regulatory approvals.

Strategic Position & Investments

Tandem’s strategic direction centers on expanding automated insulin delivery adoption, increasing international penetration, enhancing user experience through miniaturization and mobile integration, and broadening compatibility with multiple CGM systems. The company has invested heavily in software-driven diabetes management, including smartphone-controlled pump functionality and remote update infrastructure. Growth initiatives have included expanding reimbursement coverage, launching new hardware platforms, and developing next-generation algorithms intended to improve glycemic outcomes and reduce patient burden.

A notable strategic investment was the acquisition of Capillary Biomedical, aimed at improving infusion set technology and extending wear duration. Tandem has also invested in research and development related to interoperable diabetes ecosystems and advanced automated insulin delivery systems. The company’s participation in the broader digital health and connected-care market positions it within an increasingly technology-oriented diabetes management sector. Public filings and investor materials indicate continued emphasis on international growth, pipeline innovation, and expanding the installed customer base to support recurring supply revenue.

Geographic Footprint

Tandem is headquartered in San Diego, California, and maintains its largest commercial presence in the United States, which represents the majority of its revenue base according to public filings. The company has expanded internationally across Europe, Canada, Australia, and selected markets in the Middle East and Asia-Pacific through both direct operations and third-party distribution agreements. Regulatory clearances in multiple jurisdictions have supported broader adoption of its insulin delivery systems outside the U.S.

The company’s international strategy focuses on increasing access to automated insulin delivery technologies in developed diabetes care markets. Tandem has established regional commercial and support infrastructure in parts of Europe and continues to pursue geographic expansion where reimbursement frameworks and regulatory pathways support insulin pump adoption. Its products are marketed globally to endocrinology clinics, hospitals, and diabetes patients, with operational influence increasingly extending beyond North America.

Leadership & Governance

Tandem’s leadership team is composed of executives with backgrounds in medical devices, diabetes care, software-enabled healthcare, and commercial operations. The company’s governance structure follows a standard publicly traded corporate model with executive leadership oversight by a board of directors. Strategic leadership has consistently emphasized innovation in diabetes technology, interoperability, patient-centered product design, and expansion of automated insulin delivery adoption.

Key executives include:

• John Sheridan – President and Chief Executive Officer
• Leigh Vosseller – Executive Vice President and Chief Financial Officer
• Dr. Jordan Pinsker – Chief Medical Officer
• Susan Morrison – Executive Vice President and Chief Administrative Officer
• Jean-Claude Kyrillos – Executive Vice President and Chief Commercial Officer

Public company filings, investor presentations, and executive commentary indicate that management’s strategic vision centers on advancing connected diabetes care ecosystems, strengthening recurring revenue streams through consumables, and expanding Tandem’s position in the global insulin pump market.